Systemic Ltd. Announce Successful Trade Mission to Japan & Korea
News Mar 26, 2012
The Japan portion of the trip was planned by the Scottish and Japanese offices of Scottish Development International (SDI).
During the visit, Sistemic met with both existing and potential clients, and participated in a number of seminars and partnering sessions. Verna McErlane, Director of Commercial Operations, Sistemic, explained: “As the trade mission progressed, it became clear that the partnership model for drug development features highly in the plans of the pharma industry there. It was exciting to have the chance to present how the world’s second largest pharma market will benefit from Sistemic’s unique miRNA profiling products and services.”
Sistemic is pursuing an active global expansion plan for the business. Jim Reid, Sistemic’s CEO commented: “Pharma companies are looking to access technologies on a global basis, so it’s important Sistemic is recognised at this level. We are proud to have customers all over the US and Europe, as well as in Australia and Asia Pacific and we look forward to working closely with a number of new partners in Japan and Korea as a result of the trade mission.”
During the visit, Sistemic presented its SistemQC product for use in cell characterisation and QC. This is of particular interest to anyone working on cell therapies, regenerative medicine and stem cells. SistemQC is a miRNA-based fingerprint approach that provides a powerful and informative way to characterise and monitor cells lines, including stem cells, for identity, purity, safety and differentiation staging. Sistemic also presented details of SistemRNA and how it is used in drug discovery and development. SistemRNA applies a compound-centric approach identifying drug effects by associative changes in miRNA express profiles and its analysis in context. The addition of SistemRNA to the drug discovery toolbox can support strategic decision-making at key stages and maximise asset value.
Verna McErlane added: “The people we met in both countries were very welcoming and interested in innovative tools that can help them in their work. We are following up with a number of companies and planning return visits in June and September.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.